Related Experiment Video
Updated: Jun 13, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?
1Indiana University School of Medicine and Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana 46202, USA. ragarwal@iupui.edu
Abstract:
Vitamin D receptor agonists (VDRAs) inhibit the renin-angiotensin system (RAS) and reduce podocyte loss and fibrosis over and above RAS blockade. Several studies in humans show that VDRAs are antiproteinuric and have the potential to delay the progression of renal disease. Whether VDRAs will accomplish this goal among proteinuric patients with chronic kidney disease needs to be tested in randomized controlled trials.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Antihypertensive Drugs: Vasodilators
